万邦医药 reported revenue of ¥0.09B for the period ended 2026-06-30, -40.2% year on year. Net income was ¥0.00B, a 0.2% net margin on a 18.4% gross margin. The largest revenue line is 临床研究服务 at 81% of the total. Free cash flow for the period was ¥0.00B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.09B | -40.2% |
| Gross profit | ¥0.02B | — |
| Operating income | ¥-0.00B | — |
| Net income | ¥0.00B | -99.5% |
| Gross margin | 18.4% | Net margin 0.2% |
| Revenue Q/Q | +87.3% | — |
| Segment | Revenue | Share |
|---|---|---|
| 临床研究服务 | ¥0.07B | 80.8% |
| 药学研究服务 | ¥0.01B | 10.2% |
| 研发技术成果转化 | ¥0.01B | 7.7% |
| 其他(补充) | ¥0.00B | 1.3% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.07B | 81.6% |
| R&D | ¥0.02B | 18.0% |
| SG&A | ¥0.02B | 19.1% |
| Tax & other | ¥-0.00B | -3.7% |
| Item | Amount |
|---|---|
| Total assets | ¥1.82B |
| Total liabilities | ¥0.29B |
| Shareholders' equity | ¥1.53B |
| Equity / assets | 84.1% |
| Operating cash flow | ¥0.01B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥0.00B |
| Cash conversion (OCF / net income) | 584% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
上大股份 ・ 儒竞科技 ・ 国际复材 ・ 多浦乐 ・ 福赛科技 ・ 春光集团 ・ 威马农机 ・ 浙江华远 ・ 星宸科技 ・ 骏鼎达 ・ 宏鑫科技 ・ 崇德科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies